AstraZeneca Pharma India Ltd - 506820 - Board declares Interim Dividend
AstraZeneca Pharma India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 09, 2021, inter alia, has declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22. AstraZeneca Pharma India Ltd - 506820 - Outcome Of The Board Meeting Held On Monday, August 9, 2021
The Board of Directors of the Company at their meeting held today i.e, August 9, 2021, has inter-alia: 1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 9, 2021 are enclosed herewith. 2. Declared Interim Dividend of Rs. 2 per equity share for the financial year 2021-22 3. Fixed August 20, 2021 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend
Nepal receives first batch of AstraZeneca vaccine against Covid from Japan
Nepal received the first batch of AstraZeneca COVID-19 vaccine from Japan on Saturday, local media reports said.
Germany to offer Covid booster shots from September
A booster shot will also be offered to anyone who received the two-dose AstraZeneca or single-dose Johnson & Johnson vaccines, the document released by Spahn's ministry said, "in the interests of preventative healthcare". AstraZeneca Pharma India Ltd - 506820 - Board to consider Q1 results & Interim Dividend on August 09, 2021
AstraZeneca Pharma India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 09, 2021, inter alia, to:1. consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2021 (Q1).2. consider declaration of an Interim Dividend, if any, to the equity shareholders of the Company for the financial year 2021-22.The 'Trading Window' remains closed for all Designated Persons, from June 16, 2021 to August 11, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. AstraZeneca Pharma India Ltd - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 9, 2021
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2021 ,inter alia, to consider and approve i. the Unaudited Financial Results of the Company for the quarter ended June 30, 2021 ii. declaration of an Interim Dividend, if any, to the equity shareholders of the Company for the financial year 2021-22 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from June 16, 2021 to August 11, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.
Sri Lanka receives 728,460 doses of AstraZeneca vaccine from the COVAX
This is the third consignment of Covid vaccines received by Sri Lanka under the COVAX Facility Over 18 and considering the AstraZeneca vaccine? This may help you decide
Let's look at the evidence
Covishield single jab efficacy drops after 16 weeks in 60+ age grp: Report
The efficacy of the single dose of Oxford-Astrazeneca Covid-19 vaccine Covishield dropped at 16 weeks for those above the age of 60 ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated July 12, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.